StreetInsider.com News Articles

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investor conferences:

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Thu, 28 May 2026 16:01:00 -0400

2026 Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 9:20 a.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference 2026
Date:

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Mon, 18 May 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260518/26515758.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Mon, 18 May 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260518/26515758.html

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mon, 18 May 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mon, 18 May 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mon, 18 May 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mon, 18 May 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on May 15, 2026, it granted stock options to purchase an aggregate of 106,200 shares of common stock to eight new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 15 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260515/26506650.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 15 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260515/26506650.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Redmile Group, LLC

Fri, 15 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260515/26505997.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Redmile Group, LLC

Fri, 15 May 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260515/26505997.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: TORONTO DOMINION BANK

Fri, 15 May 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26503455.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: TORONTO DOMINION BANK

Fri, 15 May 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26503455.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260515/26500149.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260515/26500149.html

Form SCHEDULE 13G Stoke Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP

Fri, 15 May 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26499259.html

Form SCHEDULE 13G Stoke Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP

Fri, 15 May 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26499259.html

Form 8-K Stoke Therapeutics, Inc. For: May 07

Thu, 07 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260507/26453851.html